CU24510B1 - Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes - Google Patents

Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes

Info

Publication number
CU24510B1
CU24510B1 CU2017000044A CU20170044A CU24510B1 CU 24510 B1 CU24510 B1 CU 24510B1 CU 2017000044 A CU2017000044 A CU 2017000044A CU 20170044 A CU20170044 A CU 20170044A CU 24510 B1 CU24510 B1 CU 24510B1
Authority
CU
Cuba
Prior art keywords
adsorption
coadjuvants
composition
vaccine against
against poliomyelitis
Prior art date
Application number
CU2017000044A
Other languages
English (en)
Other versions
CU20170044A7 (es
Inventor
Rajeev Mhalasakant Dhere
Sambhaji Shankar Pisal
Rajendra Narayan Sabale
Jagdish Kamalaji Zade
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of CU20170044A7 publication Critical patent/CU20170044A7/es
Publication of CU24510B1 publication Critical patent/CU24510B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención está dirigida a métodos para inactivar poliovirus con formalina en presencia de TRIS 30mM y 50mM para obtener una recuperación máxima del antígeno D. Mediante Ia adsorción posterior de IPV en hidróxido de aluminio, las composiciones de IPV se obtienen a dosis bajas.</p>
CU2017000044A 2014-10-07 2015-10-06 Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes CU24510B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (2)

Publication Number Publication Date
CU20170044A7 CU20170044A7 (es) 2018-09-05
CU24510B1 true CU24510B1 (es) 2021-05-12

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000044A CU24510B1 (es) 2014-10-07 2015-10-06 Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes

Country Status (24)

Country Link
US (1) US10485862B2 (es)
EP (2) EP3663396A1 (es)
JP (2) JP6755243B2 (es)
KR (2) KR102510744B1 (es)
CN (2) CN113368227A (es)
AU (2) AU2015334495B2 (es)
BR (1) BR112017007089A2 (es)
CA (1) CA2963897C (es)
CU (1) CU24510B1 (es)
CY (1) CY1123078T1 (es)
DK (1) DK3204494T3 (es)
EA (1) EA201700187A1 (es)
ES (1) ES2803578T3 (es)
HU (1) HUE049104T2 (es)
LT (1) LT3204494T (es)
MX (1) MX2017004534A (es)
PE (1) PE20171132A1 (es)
PH (1) PH12017500627A1 (es)
PL (1) PL3204494T3 (es)
PT (1) PT3204494T (es)
SG (2) SG10202010814RA (es)
SI (1) SI3204494T1 (es)
UA (1) UA125788C2 (es)
WO (1) WO2016063291A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485862B2 (en) * 2014-10-07 2019-11-26 Serum Institute Of India Pvt Ltd Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
WO2017197034A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
IL264605B2 (en) * 2016-08-26 2023-04-01 Serum Inst Of India Private Ltd A multivalent vaccine
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
CN111615397A (zh) 2017-11-03 2020-09-01 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
WO2019155492A1 (en) * 2018-02-07 2019-08-15 Bharat Biotech International Limited A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
EA010057B1 (ru) * 2004-08-27 2008-06-30 Панацея Биотек Лтд. Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
ATE511398T1 (de) * 2006-09-07 2011-06-15 Glaxosmithkline Biolog Sa Inaktiviertes poliovirus mischimpfstoff
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2011074006A2 (en) 2009-12-16 2011-06-23 Serum Institute Of India Ltd. Vaccine composition
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
US10485862B2 (en) * 2014-10-07 2019-11-26 Serum Institute Of India Pvt Ltd Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Also Published As

Publication number Publication date
CN106999569B (zh) 2021-06-29
SI3204494T1 (sl) 2020-08-31
JP2017533899A (ja) 2017-11-16
HUE049104T2 (hu) 2020-08-28
PT3204494T (pt) 2020-07-10
WO2016063291A1 (en) 2016-04-28
CY1123078T1 (el) 2021-10-29
ES2803578T3 (es) 2021-01-28
KR20170063947A (ko) 2017-06-08
EP3204494B1 (en) 2020-04-01
EP3663396A1 (en) 2020-06-10
LT3204494T (lt) 2020-07-10
US10485862B2 (en) 2019-11-26
CA2963897A1 (en) 2016-04-28
KR20210021148A (ko) 2021-02-24
BR112017007089A2 (pt) 2017-12-26
CA2963897C (en) 2023-08-22
CN106999569A (zh) 2017-08-01
AU2021269395B2 (en) 2024-05-23
KR102510744B1 (ko) 2023-03-15
UA125788C2 (uk) 2022-06-08
PH12017500627A1 (en) 2017-09-25
AU2015334495A1 (en) 2017-05-25
JP6755243B2 (ja) 2020-09-16
MX2017004534A (es) 2017-10-11
CN113368227A (zh) 2021-09-10
NZ731341A (en) 2023-11-24
SG10202010814RA (en) 2020-12-30
US20170348411A1 (en) 2017-12-07
KR102219638B1 (ko) 2021-02-23
SG11201702838SA (en) 2017-05-30
JP2020203906A (ja) 2020-12-24
EA201700187A1 (ru) 2017-12-29
AU2015334495B2 (en) 2021-08-19
PL3204494T3 (pl) 2020-09-21
DK3204494T3 (da) 2020-07-06
CU20170044A7 (es) 2018-09-05
AU2021269395A1 (en) 2021-12-16
EP3204494A1 (en) 2017-08-16
PE20171132A1 (es) 2017-08-09
JP7063957B2 (ja) 2022-05-09

Similar Documents

Publication Publication Date Title
CU24510B1 (es) Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CR20180213A (es) Derivados de indol mono -o- disustituidos como inhibidores de la replicación viral del dengue
CL2017000628A1 (es) Blastosporas fúngicas estables y métodos para su producción, estabilización y uso
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CU24579B1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
MX2018008529A (es) Virus de la tilapia de tipo ortomixo.
EA201692154A1 (ru) Перорально распадающаяся пленка
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas
PE20150369A1 (es) Composicion y metodo para el control de nematodos fitoparasitos
CL2017002759A1 (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
PE20190225A1 (es) Un metodo para reducir la contaminacion de huevo
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
WO2018175580A3 (en) Development of an alternative modified live influenza b virus vaccine
AR109244A1 (es) Métodos mejorados para la inactivación de enterovirus y la adsorción sobre coadyuvantes, y composiciones de vacunas con dosis reducidas obtenidas con ellos
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
AR113831A1 (es) Métodos para desactivar un virus de zika y para determinar la desactivación total